Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 24 entries
Sorted by: Best Match Show Resources per page
Electrolyte-Induced Surface Transformation and Transition-Metal Dissolution of Fully Delithiated LiNi.

Langmuir : the ACS journal of surfaces and colloids

Faenza NV, Lebens-Higgins ZW, Mukherjee P, Sallis S, Pereira N, Badway F, Halajko A, Ceder G, Cosandey F, Piper LFJ, Amatucci GG.
PMID: 28595010
Langmuir. 2017 Sep 19;33(37):9333-9353. doi: 10.1021/acs.langmuir.7b00863. Epub 2017 Jun 22.

Enabling practical utilization of layered R3̅m positive electrodes near full delithiation requires an enhanced understanding of the complex electrode-electrolyte interactions that often induce failure. Using Li[Ni

Cite
Faenza NV, Lebens-Higgins ZW, Mukherjee P, et al. Electrolyte-Induced Surface Transformation and Transition-Metal Dissolution of Fully Delithiated LiNi. Langmuir. 2017;33(37):9333-9353doi: 10.1021/acs.langmuir.7b00863.
Faenza, N. V., Lebens-Higgins, Z. W., Mukherjee, P., Sallis, S., Pereira, N., Badway, F., Halajko, A., Ceder, G., Cosandey, F., Piper, L. F. J., & Amatucci, G. G. (2017). Electrolyte-Induced Surface Transformation and Transition-Metal Dissolution of Fully Delithiated LiNi. Langmuir : the ACS journal of surfaces and colloids, 33(37), 9333-9353. https://doi.org/10.1021/acs.langmuir.7b00863
Faenza, Nicholas V, et al. "Electrolyte-Induced Surface Transformation and Transition-Metal Dissolution of Fully Delithiated LiNi." Langmuir : the ACS journal of surfaces and colloids vol. 33,37 (2017): 9333-9353. doi: https://doi.org/10.1021/acs.langmuir.7b00863
Faenza NV, Lebens-Higgins ZW, Mukherjee P, Sallis S, Pereira N, Badway F, Halajko A, Ceder G, Cosandey F, Piper LFJ, Amatucci GG. Electrolyte-Induced Surface Transformation and Transition-Metal Dissolution of Fully Delithiated LiNi. Langmuir. 2017 Sep 19;33(37):9333-9353. doi: 10.1021/acs.langmuir.7b00863. Epub 2017 Jun 22. PMID: 28595010.
Copy Download .nbib Format: NLM
Impact of adiponectin overexpression on allergic airways responses in mice.

Journal of allergy

Verbout NG, Benedito L, Williams AS, Kasahara DI, Wurmbrand AP, Si H, Halayko AJ, Hug C, Shore SA.
PMID: 23861690
J Allergy (Cairo). 2013;2013:349520. doi: 10.1155/2013/349520. Epub 2013 Jun 04.

Obesity is an important risk factor for asthma. Obese individuals have decreased circulating adiponectin, an adipose-derived hormone with anti-inflammatory properties. We hypothesized that transgenic overexpression of adiponectin would attenuate allergic airways inflammation and mucous hyperplasia in mice. To test...

Cite
Verbout NG, Benedito L, Williams AS, et al. Impact of adiponectin overexpression on allergic airways responses in mice. J Allergy (Cairo). 2013;2013:349520doi: 10.1155/2013/349520.
Verbout, N. G., Benedito, L., Williams, A. S., Kasahara, D. I., Wurmbrand, A. P., Si, H., Halayko, A. J., Hug, C., & Shore, S. A. (2013). Impact of adiponectin overexpression on allergic airways responses in mice. Journal of allergy, 2013349520. https://doi.org/10.1155/2013/349520
Verbout, Norah G, et al. "Impact of adiponectin overexpression on allergic airways responses in mice." Journal of allergy vol. 2013 (2013): 349520. doi: https://doi.org/10.1155/2013/349520
Verbout NG, Benedito L, Williams AS, Kasahara DI, Wurmbrand AP, Si H, Halayko AJ, Hug C, Shore SA. Impact of adiponectin overexpression on allergic airways responses in mice. J Allergy (Cairo). 2013;2013:349520. doi: 10.1155/2013/349520. Epub 2013 Jun 04. PMID: 23861690; PMCID: PMC3686156.
Copy Download .nbib Format: NLM
Src mediates cytokine-stimulated gene expression in airway myocytes through ERK MAPK.

Cell communication and signaling : CCS

Singer CA, Lontay B, Unruh H, Halayko AJ, Gerthoffer WT.
PMID: 21599982
Cell Commun Signal. 2011 May 20;9(1):14. doi: 10.1186/1478-811X-9-14.

The p38 and extracellular signal-regulated kinases (ERK) mitogen-activated protein kinases (MAPK) participate in cytokine-stimulated inflammatory gene expression in airway smooth muscle cells. The following study was undertaken to determine whether Src tyrosine kinases are signaling intermediaries upstream of cytokine-stimulated...

Cite
Singer CA, Lontay B, Unruh H, et al. Src mediates cytokine-stimulated gene expression in airway myocytes through ERK MAPK. Cell Commun Signal. 2011;9(1):14doi: 10.1186/1478-811X-9-14.
Singer, C. A., Lontay, B., Unruh, H., Halayko, A. J., & Gerthoffer, W. T. (2011). Src mediates cytokine-stimulated gene expression in airway myocytes through ERK MAPK. Cell communication and signaling : CCS, 9(1), 14. https://doi.org/10.1186/1478-811X-9-14
Singer, Cherie A, et al. "Src mediates cytokine-stimulated gene expression in airway myocytes through ERK MAPK." Cell communication and signaling : CCS vol. 9,1 (2011): 14. doi: https://doi.org/10.1186/1478-811X-9-14
Singer CA, Lontay B, Unruh H, Halayko AJ, Gerthoffer WT. Src mediates cytokine-stimulated gene expression in airway myocytes through ERK MAPK. Cell Commun Signal. 2011 May 20;9(1):14. doi: 10.1186/1478-811X-9-14. PMID: 21599982; PMCID: PMC3123314.
Copy Download .nbib Format: NLM
Retraction Note: The anti-proliferative and anti-inflammatory response of COPD airway smooth muscle cells to hydrogen sulfide.

Respiratory research

Perry MM, Tildy B, Papi A, Casolari P, Caramori G, Rempel KL, Halayko AJ, Adcock I, Chung KF.
PMID: 34433461
Respir Res. 2021 Aug 25;22(1):235. doi: 10.1186/s12931-021-01816-7.

No abstract available.

Cite
Perry MM, Tildy B, Papi A, et al. Retraction Note: The anti-proliferative and anti-inflammatory response of COPD airway smooth muscle cells to hydrogen sulfide. Respir Res. 2021;22(1):235doi: 10.1186/s12931-021-01816-7.
Perry, M. M., Tildy, B., Papi, A., Casolari, P., Caramori, G., Rempel, K. L., Halayko, A. J., Adcock, I., & Chung, K. F. (2021). Retraction Note: The anti-proliferative and anti-inflammatory response of COPD airway smooth muscle cells to hydrogen sulfide. Respiratory research, 22(1), 235. https://doi.org/10.1186/s12931-021-01816-7
Perry, Mark M, et al. "Retraction Note: The anti-proliferative and anti-inflammatory response of COPD airway smooth muscle cells to hydrogen sulfide." Respiratory research vol. 22,1 (2021): 235. doi: https://doi.org/10.1186/s12931-021-01816-7
Perry MM, Tildy B, Papi A, Casolari P, Caramori G, Rempel KL, Halayko AJ, Adcock I, Chung KF. Retraction Note: The anti-proliferative and anti-inflammatory response of COPD airway smooth muscle cells to hydrogen sulfide. Respir Res. 2021 Aug 25;22(1):235. doi: 10.1186/s12931-021-01816-7. PMID: 34433461; PMCID: PMC8385973.
Copy Download .nbib Format: NLM
Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease.

Annals of the American Thoracic Society

Johannson KA, Lethebe BC, Assayag D, Fisher JH, Kolb M, Morisset J, Shapera S, Gershon AS, Hambly N, Khalil N, To T, Fell CD, Cox G, Manganas H, Halayko AJ, Marcoux V, Sadatsafavi M, Wilcox PG, Bertazzon S, Ryerson CJ.
PMID: 34033739
Ann Am Thorac Soc. 2021 May 25; doi: 10.1513/AnnalsATS.202102-216OC. Epub 2021 May 25.

RATIONALE: Early access to subspecialty care is associated with improved outcomes for patients with fibrotic interstitial lung disease (ILD). Access to ILD care may be limited for patients living far from subspecialty clinics.OBJECTIVE: To test the hypothesis that greater...

Cite
Johannson KA, Lethebe BC, Assayag D, et al. Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Ann Am Thorac Soc. 2021;doi: 10.1513/AnnalsATS.202102-216OC.
Johannson, K. A., Lethebe, B. C., Assayag, D., Fisher, J. H., Kolb, M., Morisset, J., Shapera, S., Gershon, A. S., Hambly, N., Khalil, N., To, T., Fell, C. D., Cox, G., Manganas, H., Halayko, A. J., Marcoux, V., Sadatsafavi, M., Wilcox, P. G., Bertazzon, S., & Ryerson, C. J. (2021). Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, . https://doi.org/10.1513/AnnalsATS.202102-216OC
Johannson, Kerri A, et al. "Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease." Annals of the American Thoracic Society vol. (2021). doi: https://doi.org/10.1513/AnnalsATS.202102-216OC
Johannson KA, Lethebe BC, Assayag D, Fisher JH, Kolb M, Morisset J, Shapera S, Gershon AS, Hambly N, Khalil N, To T, Fell CD, Cox G, Manganas H, Halayko AJ, Marcoux V, Sadatsafavi M, Wilcox PG, Bertazzon S, Ryerson CJ. Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Ann Am Thorac Soc. 2021 May 25; doi: 10.1513/AnnalsATS.202102-216OC. Epub 2021 May 25. PMID: 34033739.
Copy Download .nbib Format: NLM
Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease.

Annals of the American Thoracic Society

Johannson KA, Lethebe BC, Assayag D, Fisher JH, Kolb M, Morisset J, Shapera S, Gershon AS, Hambly N, Khalil N, To T, Fell CD, Cox G, Manganas H, Halayko AJ, Marcoux V, Sadatsafavi M, Wilcox PG, Bertazzon S, Ryerson CJ.
PMID: 34033739
Ann Am Thorac Soc. 2022 Jan;19(1):20-27. doi: 10.1513/AnnalsATS.202102-216OC.

No abstract available.

Cite
Johannson KA, Lethebe BC, Assayag D, et al. Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Ann Am Thorac Soc. 2022;19(1):20-27doi: 10.1513/AnnalsATS.202102-216OC.
Johannson, K. A., Lethebe, B. C., Assayag, D., Fisher, J. H., Kolb, M., Morisset, J., Shapera, S., Gershon, A. S., Hambly, N., Khalil, N., To, T., Fell, C. D., Cox, G., Manganas, H., Halayko, A. J., Marcoux, V., Sadatsafavi, M., Wilcox, P. G., Bertazzon, S., & Ryerson, C. J. (2022). Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 19(1), 20-27. https://doi.org/10.1513/AnnalsATS.202102-216OC
Johannson, Kerri A, et al. "Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease." Annals of the American Thoracic Society vol. 19,1 (2022): 20-27. doi: https://doi.org/10.1513/AnnalsATS.202102-216OC
Johannson KA, Lethebe BC, Assayag D, Fisher JH, Kolb M, Morisset J, Shapera S, Gershon AS, Hambly N, Khalil N, To T, Fell CD, Cox G, Manganas H, Halayko AJ, Marcoux V, Sadatsafavi M, Wilcox PG, Bertazzon S, Ryerson CJ. Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Ann Am Thorac Soc. 2022 Jan;19(1):20-27. doi: 10.1513/AnnalsATS.202102-216OC. PMID: 34033739.
Copy Download .nbib Format: NLM
The CAnadian REgistry for Pulmonary Fibrosis (CARE-PF): Design and rationale of a national pulmonary fibrosis registry.

Canadian respiratory journal

Ryerson CJ, Tan B, Fell CD, Manganas H, Shapera S, Mittoo S, Sadatsafavi M, To T, Gershon A, Fisher JH, Johannson KA, Hambly N, Khalil N, Marras TK, Morisset J, Wilcox PG, Halayko AJ, Khan MA, Kolb M.
PMID: 26523546
Can Respir J. 2015 Nov 02; Epub 2015 Nov 02.

No abstract available.

Cite
Ryerson CJ, Tan B, Fell CD, et al. The CAnadian REgistry for Pulmonary Fibrosis (CARE-PF): Design and rationale of a national pulmonary fibrosis registry. Can Respir J. 2015;
Ryerson, C. J., Tan, B., Fell, C. D., Manganas, H., Shapera, S., Mittoo, S., Sadatsafavi, M., To, T., Gershon, A., Fisher, J. H., Johannson, K. A., Hambly, N., Khalil, N., Marras, T. K., Morisset, J., Wilcox, P. G., Halayko, A. J., Khan, M. A., & Kolb, M. (2015). The CAnadian REgistry for Pulmonary Fibrosis (CARE-PF): Design and rationale of a national pulmonary fibrosis registry. Canadian respiratory journal, .
Ryerson, Christopher J, et al. "The CAnadian REgistry for Pulmonary Fibrosis (CARE-PF): Design and rationale of a national pulmonary fibrosis registry." Canadian respiratory journal vol. (2015).
Ryerson CJ, Tan B, Fell CD, Manganas H, Shapera S, Mittoo S, Sadatsafavi M, To T, Gershon A, Fisher JH, Johannson KA, Hambly N, Khalil N, Marras TK, Morisset J, Wilcox PG, Halayko AJ, Khan MA, Kolb M. The CAnadian REgistry for Pulmonary Fibrosis (CARE-PF): Design and rationale of a national pulmonary fibrosis registry. Can Respir J. 2015 Nov 02; Epub 2015 Nov 02. PMID: 26523546.
Copy Download .nbib Format: NLM
TNF up-regulates Pentraxin3 expression in human airway smooth muscle cells via JNK and ERK1/2 MAPK pathways.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

Zhang J, Koussih L, Shan L, Halayko AJ, Chen BK, Gounni AS.
PMID: 26644796
Allergy Asthma Clin Immunol. 2015 Dec 07;11:37. doi: 10.1186/s13223-015-0104-y. eCollection 2015.

BACKGROUND: Long pentraxin 3 (PTX3) is a novel candidate marker for inflammation in many chronic diseases. As a soluble pattern recognition receptor, PTX3 is involved in amplification of inflammatory reactions and regulation of innate immunity. Previously, we demonstrate that...

Cite
Zhang J, Koussih L, Shan L, et al. TNF up-regulates Pentraxin3 expression in human airway smooth muscle cells via JNK and ERK1/2 MAPK pathways. Allergy Asthma Clin Immunol. 2015;11:37doi: 10.1186/s13223-015-0104-y.
Zhang, J., Koussih, L., Shan, L., Halayko, A. J., Chen, B. K., & Gounni, A. S. (2015). TNF up-regulates Pentraxin3 expression in human airway smooth muscle cells via JNK and ERK1/2 MAPK pathways. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 1137. https://doi.org/10.1186/s13223-015-0104-y
Zhang, Jingbo, et al. "TNF up-regulates Pentraxin3 expression in human airway smooth muscle cells via JNK and ERK1/2 MAPK pathways." Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology vol. 11 (2015): 37. doi: https://doi.org/10.1186/s13223-015-0104-y
Zhang J, Koussih L, Shan L, Halayko AJ, Chen BK, Gounni AS. TNF up-regulates Pentraxin3 expression in human airway smooth muscle cells via JNK and ERK1/2 MAPK pathways. Allergy Asthma Clin Immunol. 2015 Dec 07;11:37. doi: 10.1186/s13223-015-0104-y. eCollection 2015. PMID: 26644796; PMCID: PMC4671218.
Copy Download .nbib Format: NLM
Integrating Proteomes for Lung Tissues and Lavage Reveals Pathways That Link Responses in Allergen-Challenged Mice.

ACS omega

Mahood TH, Pascoe CD, Karakach TK, Jha A, Basu S, Ezzati P, Spicer V, Mookherjee N, Halayko AJ.
PMID: 33490776
ACS Omega. 2021 Jan 05;6(2):1171-1189. doi: 10.1021/acsomega.0c04269. eCollection 2021 Jan 19.

To capture interplay between biological pathways, we analyzed the proteome from matched lung tissues and bronchoalveolar lavage fluid (BALF) of individual allergen-naïve and house dust mite (HDM)-challenged BALB/c mice, a model of allergic asthma. Unbiased label-free liquid chromatography with...

Cite
Mahood TH, Pascoe CD, Karakach TK, et al. Integrating Proteomes for Lung Tissues and Lavage Reveals Pathways That Link Responses in Allergen-Challenged Mice. ACS Omega. 2021;6(2):1171-1189doi: 10.1021/acsomega.0c04269.
Mahood, T. H., Pascoe, C. D., Karakach, T. K., Jha, A., Basu, S., Ezzati, P., Spicer, V., Mookherjee, N., & Halayko, A. J. (2021). Integrating Proteomes for Lung Tissues and Lavage Reveals Pathways That Link Responses in Allergen-Challenged Mice. ACS omega, 6(2), 1171-1189. https://doi.org/10.1021/acsomega.0c04269
Mahood, Thomas H, et al. "Integrating Proteomes for Lung Tissues and Lavage Reveals Pathways That Link Responses in Allergen-Challenged Mice." ACS omega vol. 6,2 (2021): 1171-1189. doi: https://doi.org/10.1021/acsomega.0c04269
Mahood TH, Pascoe CD, Karakach TK, Jha A, Basu S, Ezzati P, Spicer V, Mookherjee N, Halayko AJ. Integrating Proteomes for Lung Tissues and Lavage Reveals Pathways That Link Responses in Allergen-Challenged Mice. ACS Omega. 2021 Jan 05;6(2):1171-1189. doi: 10.1021/acsomega.0c04269. eCollection 2021 Jan 19. PMID: 33490776; PMCID: PMC7818314.
Copy Download .nbib Format: NLM
Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease.

Annals of the American Thoracic Society

Johannson KA, Lethebe BC, Assayag D, Fisher JH, Kolb M, Morisset J, Shapera S, Gershon AS, Hambly N, Khalil N, To T, Fell CD, Cox G, Manganas H, Halayko AJ, Marcoux V, Sadatsafavi M, Wilcox PG, Bertazzon S, Ryerson CJ.
PMID: 34033739
Ann Am Thorac Soc. 2022 Jan;19(1):20-27. doi: 10.1513/AnnalsATS.202102-216OC.

No abstract available.

Cite
Johannson KA, Lethebe BC, Assayag D, et al. Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Ann Am Thorac Soc. 2022;19(1):20-27doi: 10.1513/AnnalsATS.202102-216OC.
Johannson, K. A., Lethebe, B. C., Assayag, D., Fisher, J. H., Kolb, M., Morisset, J., Shapera, S., Gershon, A. S., Hambly, N., Khalil, N., To, T., Fell, C. D., Cox, G., Manganas, H., Halayko, A. J., Marcoux, V., Sadatsafavi, M., Wilcox, P. G., Bertazzon, S., & Ryerson, C. J. (2022). Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 19(1), 20-27. https://doi.org/10.1513/AnnalsATS.202102-216OC
Johannson, Kerri A, et al. "Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease." Annals of the American Thoracic Society vol. 19,1 (2022): 20-27. doi: https://doi.org/10.1513/AnnalsATS.202102-216OC
Johannson KA, Lethebe BC, Assayag D, Fisher JH, Kolb M, Morisset J, Shapera S, Gershon AS, Hambly N, Khalil N, To T, Fell CD, Cox G, Manganas H, Halayko AJ, Marcoux V, Sadatsafavi M, Wilcox PG, Bertazzon S, Ryerson CJ. Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Ann Am Thorac Soc. 2022 Jan;19(1):20-27. doi: 10.1513/AnnalsATS.202102-216OC. PMID: 34033739.
Copy Download .nbib Format: NLM
Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease.

Respiratory research

Chen T, Tsai APY, Hur SA, Wong AW, Sadatsafavi M, Fisher JH, Johannson KA, Assayag D, Morisset J, Shapera S, Khalil N, Fell CD, Manganas H, Cox G, To T, Gershon AS, Hambly N, Halayko AJ, Wilcox PG, Kolb M, Ryerson CJ.
PMID: 34238283
Respir Res. 2021 Jul 08;22(1):202. doi: 10.1186/s12931-021-01790-0.

RATIONALE: The University of California, San Diego Shortness of Breath Questionnaire (UCSDSOBQ) is a frequently used domain-specific dyspnea questionnaire; however, there is little information available regarding its use and minimum important difference (MID) in fibrotic interstitial lung disease (ILD)....

Cite
Chen T, Tsai APY, Hur SA, et al. Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respir Res. 2021;22(1):202doi: 10.1186/s12931-021-01790-0.
Chen, T., Tsai, A. P. Y., Hur, S. A., Wong, A. W., Sadatsafavi, M., Fisher, J. H., Johannson, K. A., Assayag, D., Morisset, J., Shapera, S., Khalil, N., Fell, C. D., Manganas, H., Cox, G., To, T., Gershon, A. S., Hambly, N., Halayko, A. J., Wilcox, P. G., Kolb, M., & Ryerson, C. J. (2021). Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory research, 22(1), 202. https://doi.org/10.1186/s12931-021-01790-0
Chen, Tao, et al. "Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease." Respiratory research vol. 22,1 (2021): 202. doi: https://doi.org/10.1186/s12931-021-01790-0
Chen T, Tsai APY, Hur SA, Wong AW, Sadatsafavi M, Fisher JH, Johannson KA, Assayag D, Morisset J, Shapera S, Khalil N, Fell CD, Manganas H, Cox G, To T, Gershon AS, Hambly N, Halayko AJ, Wilcox PG, Kolb M, Ryerson CJ. Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respir Res. 2021 Jul 08;22(1):202. doi: 10.1186/s12931-021-01790-0. PMID: 34238283; PMCID: PMC8265065.
Copy Download .nbib Format: NLM
Association of Body Mass Index and Change in Weight with Mortality in Patients with Fibrotic Interstitial Lung Disease.

Chest

Comes A, Wong AW, Fisher JH, Morisset J, Johannson KA, Farrand E, Fell CD, Kolb M, Manganas H, Cox G, Gershon AS, Halayko AJ, Hambly N, Khalil N, Sadatsafavi M, Shapera S, To T, Wilcox PG, Collard HR, Ryerson CJ.
PMID: 34788669
Chest. 2021 Nov 14; doi: 10.1016/j.chest.2021.11.008. Epub 2021 Nov 14.

BACKGROUND: Mortality risk assessment in interstitial lung disease (ILD) is challenging. Our objective was to determine the prognostic significance of body mass index (BMI) and change in weight in the most common fibrotic ILD subtypes.RESEARCH QUESTION: Could BMI and...

Cite
Comes A, Wong AW, Fisher JH, et al. Association of Body Mass Index and Change in Weight with Mortality in Patients with Fibrotic Interstitial Lung Disease. Chest. 2021;doi: 10.1016/j.chest.2021.11.008.
Comes, A., Wong, A. W., Fisher, J. H., Morisset, J., Johannson, K. A., Farrand, E., Fell, C. D., Kolb, M., Manganas, H., Cox, G., Gershon, A. S., Halayko, A. J., Hambly, N., Khalil, N., Sadatsafavi, M., Shapera, S., To, T., Wilcox, P. G., Collard, H. R., & Ryerson, C. J. (2021). Association of Body Mass Index and Change in Weight with Mortality in Patients with Fibrotic Interstitial Lung Disease. Chest, . https://doi.org/10.1016/j.chest.2021.11.008
Comes, Alessia, et al. "Association of Body Mass Index and Change in Weight with Mortality in Patients with Fibrotic Interstitial Lung Disease." Chest vol. (2021). doi: https://doi.org/10.1016/j.chest.2021.11.008
Comes A, Wong AW, Fisher JH, Morisset J, Johannson KA, Farrand E, Fell CD, Kolb M, Manganas H, Cox G, Gershon AS, Halayko AJ, Hambly N, Khalil N, Sadatsafavi M, Shapera S, To T, Wilcox PG, Collard HR, Ryerson CJ. Association of Body Mass Index and Change in Weight with Mortality in Patients with Fibrotic Interstitial Lung Disease. Chest. 2021 Nov 14; doi: 10.1016/j.chest.2021.11.008. Epub 2021 Nov 14. PMID: 34788669.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 24 entries